South Korean regulators have forced Johnson & Johnson to halt production at an over-the-counter drug plant, and Indian watchdogs are doing the same at a consumer healthcare facility in their country.
Australia's Novotech has sold off a 30% stake to private equity firm Mercury Capital, planning to use the money to spread its reach across Asia.
Drugmakers hope to export their success to emerging markets so they can reap big rewards, but Johnson & Johnson's Janssen unit appears to have taken a backward approach in South Korea, where it is in hot water over a recall of Children's Tylenol products.
Hangzhou, China-based Ascletis aims to develop the candidate, called TMC310911, as an affordable and superior treatment for HIV patients in China, company CEO Jinzi Wu told FierceBiotech in an interview.
India's Biocon reported a huge fiscal year for its CRO arm, growing 36% over the previous year and becoming the largest clinical research provider in the country, the company said.
The Japanese drugmaker will use the plant to tap growing demand in that country, as well as an export base for other emerging markets in Asia.
CardioDx, a 2012 Fierce 15 winner, has partnered with India's Core Diagnostics to distribute its coronary artery disease test in the country's burgeoning market.
Drugmakers from around the world are hustling to expand in China's fast-growing drug market. Merck just opened a $120 million packaging plant there and now Japan's Eisai is set to build a new plant to make parenteral products in Suzhou, Jiangsu.
Four years ago, a federal agency in Thailand began building a plant intended to produce enough flu vaccine to protect the country in case of a pandemic. But anticorruption investigators for the current government now want answers as to why the plant is two years overdue.
India's government wants the country to become the world's preeminent low-cost vaccine supplier, but it will first have to overcome problems of its own making.